WINTON GROUP Ltd Buys 1,006 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

WINTON GROUP Ltd raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,343 shares of the company’s stock after acquiring an additional 1,006 shares during the quarter. WINTON GROUP Ltd’s holdings in Medpace were worth $1,111,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. Pallas Capital Advisors LLC grew its stake in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after buying an additional 2,101 shares during the last quarter. Barclays PLC grew its stake in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC grew its position in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares during the period. Janus Henderson Group PLC grew its position in shares of Medpace by 10.0% during the 3rd quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock valued at $14,722,000 after acquiring an additional 4,023 shares during the period. Finally, SYM FINANCIAL Corp bought a new stake in Medpace during the fourth quarter valued at about $320,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the topic of a number of recent analyst reports. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised shares of Medpace to a “hold” rating in a report on Monday, March 24th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $376.30.

Medpace Stock Down 1.3 %

MEDP opened at $312.36 on Friday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The firm has a 50-day simple moving average of $335.90 and a two-hundred day simple moving average of $339.07. The company has a market capitalization of $9.52 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.